进展性转移性NSCLC免疫治疗.pptxVIP

下载本文档

16
0
约2.01万字
约 29页
2018-06-20 发布于上海
举报
版权申诉

进展性转移性NSCLC免疫治疗.pptx

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Immunotherapy for Progressive Metastatic NSCLCHelena A. Yu, MDAssistant AttendingDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkAbout These SlidesSlide credit: /Please feel free to use, update, and share some or all of these slides in your noncommercial presentations to colleagues or patientsWhen using our slides, please retain the source attribution:These slides may not be published, posted online, or used in commercial presentations without permission. Please contact mailto:permissions@permissions@ for detailsFaculty DisclosureHelena A. Yu, MD, has disclosed that she has received consulting fees from AstraZeneca and funds for research support paid to her institution from Astellas, AstraZeneca, Daiichi, Lilly, and Novartis. Presentation OutlineSlide credit: /Second-line immunotherapyImmunotherapy in EGFR/ALK-positive patientsProgression after first-line immunotherapy with or without chemotherapyTreatment beyond progressionChemotherapy after immunotherapy—enhanced response?Overview of Immunotherapy as Second-line or Subsequent Therapy for Advanced NSCLCCompoundTrialORR, %PFS, Mos (Range)OS, Mos (Range)NivolumabCheckMate 017[1]20.03.5 (2.1-4.9)9.2 (7.3-13.3)CheckMate 057[2]19.22.3 (2.2-3.3)12.2 (9.7-15.0)PembrolizumabKEYNOTE 010*[3]183.9 (3.1-4.1)4.0 (2.7-4.3)10.4 (9.4-11.9)12.7 (10.0-17.3)AtezolizumabOAK[4]14.02.8 (2.6-3.0)13.8 (11.8-15.7)AvelumabJAVELIN[5]12.011.6 wks (8.4-13.7) wks8.4 (7.3-10.6)DurvalumabATLANTIC??[6]7.5 (3.1-14.9)16.4 (10.8-23.5)30.9 (20.2-43.3)1.9 (1.8-1.9)3.3 (1.9-3.7)2.4 (1.8-5.5)9.3 (5.9-10.8)10.9 (8.6-13.6)NR (5.9-NC)Slide credit: /*2 and 10 mg/kg at PD-L1 TPS ≥ 1%. ?PD-L1 25%, ≥ 25%, and ≥ 90%. ?EGFR/ALK wild-type patients.1. Brahmer J, et al. N Engl J Med. 2015;373:123-135. 2. Borghaei H, et al. N Engl J Med. 2015;373:1627-1639. 3. Herbst RS, et al. Lancet. 2016;387:1540-1550. 4. Rittmeyer A, et al. Lancet. 2017;389:255-265. 5. Gulley JL, et al. Lancet Oncol. 2017;18:599-610. 6. Garassino MC, et al. Lancet O